Compare Amgen, Inc. (AMGN) vs iShares MBS ETF (MBB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs iShares MBS ETF — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while iShares MBS ETF trades at $93.72. The key difference: Amgen, Inc. pays a 2.77% dividend while iShares MBS ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, iShares MBS ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | MBB | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | — |
52-Week High | $388.16 | $96.91 |
52-Week Low | $271.18 | $92.46 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
MBB, the iShares MBS ETF tracking U.S. mortgage-backed securities, trades at $93.72, down 0.11% on the day. Technical indicators signal a bearish trend with moving averages uniformly negative, though oscillators are neutral. Recent news highlights institutional activity, with firms like Aureum Wealth Management opening new positions (Defense World, April 23, 2026) while others reduced stakes. The ETF offers a dividend yield, with recent payouts around $0.33-$0.34 per share.
The outlook for MBB is mixed, with bearish technicals offset by steady income appeal. Risks include interest rate sensitivity and mortgage market volatility, but its role as a ultra-safe real estate ETF (24/7 Wall Street, April 18, 2026) may attract defensive investors. Monitoring Federal Reserve policy and housing data is critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →
